Checchi Capital Advisers LLC Purchases 110 Shares of Zoetis Inc. (NYSE:ZTS)

Checchi Capital Advisers LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,122 shares of the company’s stock after buying an additional 110 shares during the period. Checchi Capital Advisers LLC’s holdings in Zoetis were worth $509,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC boosted its stake in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares during the last quarter. Darwin Wealth Management LLC bought a new position in Zoetis during the third quarter valued at approximately $31,000. First Personal Financial Services bought a new position in Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new position in Zoetis during the third quarter valued at approximately $33,000. Finally, Dunhill Financial LLC boosted its stake in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.16% of the company’s stock.

Zoetis Trading Down 2.1 %

Shares of NYSE ZTS opened at $164.99 on Thursday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business has a fifty day simple moving average of $166.22 and a two-hundred day simple moving average of $177.58. The firm has a market cap of $73.88 billion, a PE ratio of 30.16, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. Zoetis’s dividend payout ratio is presently 36.56%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of recent research reports. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Piper Sandler reduced their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Finally, Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $215.40.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.